Skip to main content
. 2013 Aug 15;9(8):e1003501. doi: 10.1371/journal.ppat.1003501

Figure 6. Picostim/IL2 expansion of Vγ2Vδ2 T cells led to enhanced pulmonary immune responses of Mtb peptide-specific αβ CD4+/CD8+ T effector cells, and Picostim/IL2-expanded Vγ2Vδ2 T cells in vivo could produce IL-12 constitutive without the need for in vitro stimulation(student t test used for p values).

Figure 6

(a). Picostim/IL-2 treated macaques exhibited greater percentage numbers of PPD-specific IFNγ-producing CD4+ T cells (top) and CD8+ T cells(bottom) in BALF than saline/BSA-treated or IL-2-treated macaques. Effector cells were measured by ICS after PPD stimulation(n = 9/group). See Fig. S5 in Text S1 for T effector cells detected by direct ICS without antigen stimulation in vitro. (b). Representative cytometry histograms for Vγ2Vδ2 T cells producing IL-12 and graph data (bottom panel) for numbers of IL-12-producing Vγ2Vδ2 T cells from Picostim/IL-2, IL-2 alone or saline treatment of Mtb-infected macaques(n = 4/group). T effector cells producing IL-12 cytokine (clone C8.6, Miltenyi) were measured by the direct ICS method in the absence of antigen stimulation, analyzed by flow cytometry (see Methods), and expressed objectively as percents of total CD3+ T cells as cells were gated on CD3. Note that numbers in the upper left quadruple presumably denote percentages of IL12-producing CD3+ αβ+ T cells as they do not express γδ TCR.